Search results
Results From The WOW.Com Content Network
Sometimes, it’s hard to know who or what to believe. Such is the case when it comes to the ongoing U.S. Securities and Exchange Commission (SEC) probe into Cassava Sciences (NASDAQ:SAVA). As the ...
As I discussed in my last article on Cassava Sciences (NASDAQ:SAVA), controversy continues to weigh on the performance of SAVA stock. Over the past week, shares in the clinical-stage biotech firm ...
Not long afterward, however, Cassava disputed the legitimacy of that report. These twists and turns in the ongoing story make it difficult to recommend SAVA stock with confidence now. Let’s ...
Rumors about the Securities and Exchange Commission (or SEC) clearing its investigation of the scandal-tarnished biotech firm resulted in a big spike for SAVA stock on Sept. 22.
Since last August, biotech firm Cassava Sciences (NASDAQ:SAVA) has had a big issue that’s weighed on SAVA stock. Source: Postmodern Studio / Shutterstock.com That would be the citizen petition ...
Cassava Sciences (NASDAQ:SAVA) stands to gain a good deal this year. This will all depend on the company’s Phase 3 clinical trials progress in the results on actual patients with Alzheimer’s ...
The stock market is full of ups and downs, which isn’t necessarily a bad thing. Shares of clinical-stage biotechnology company Cassava Sciences (NASDAQ:SAVA) are prone to peaks and valleys, but ...
Since making some big moves last month Cassava Sciences (NASDAQ:SAVA) stock has largely traded sideways. Yet while SAVA stock has been acting less wild, don’t blame it on a lack of new developments.